Repository logo
  • Log In
    Log in via Symplectic to deposit your publication(s).
Repository logo
  • About
  • Communities & Collections
  • Advanced Search
  • Statistics
  • Log In
    Log in via Symplectic to deposit your publication(s).
  1. Home
  2. Faculty of Medicine
  3. Faculty of Medicine
  4. Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN-augmenting activity in airway epithelium
 
  • Details
Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN-augmenting activity in airway epithelium
File(s)
jac.dkw222.full.pdf (762.26 KB)
Published version
J. Antimicrob. Chemother.-2016-Porter-2767-81.pdf (770.81 KB)
Published version
Author(s)
Porter, JD
Watson, J
Groves, H
Dhariwal, J
Almond, MH
more
Type
Journal Article
Abstract
Background Exacerbations of asthma and COPD are triggered by rhinoviruses. Uncontrolled inflammatory pathways, pathogenic bacterial burden and impaired antiviral immunity are thought to be important factors in disease severity and duration. Macrolides including azithromycin are often used to treat the above diseases, but exhibit variable levels of efficacy. Inhaled corticosteroids are also readily used in treatment, but may lack specificity. Ideally, new treatment alternatives should suppress unwanted inflammation, but spare beneficial antiviral immunity.

Methods In the present study, we screened 225 novel macrolides and tested them for enhanced antiviral activity against rhinovirus, as well as anti-inflammatory activity and activity against Gram-positive and Gram-negative bacteria. Primary bronchial epithelial cells were grown from 10 asthmatic individuals and the effects of macrolides on rhinovirus replication were also examined. Another 30 structurally similar macrolides were also examined.

Results The oleandomycin derivative Mac5, compared with azithromycin, showed superior induction (up to 5-fold, EC50 = 5–11 μM) of rhinovirus-induced type I IFNβ, type III IFNλ1 and type III IFNλ2/3 mRNA and the IFN-stimulated genes viperin and MxA, yet had no effect on IL-6 and IL-8 mRNA. Mac5 also suppressed rhinovirus replication at 48 h, proving antiviral activity. Mac5 showed antibacterial activity against Gram-positive Streptococcus pneumoniae; however, it did not have any antibacterial properties compared with azithromycin when used against Gram-negative Escherichia coli (as a model organism) and also the respiratory pathogens Pseudomonas aeruginosa and non-typeable Haemophilus influenzae. Further non-toxic Mac5 derivatives were identified with various anti-inflammatory, antiviral and antibacterial activities.

Conclusions The data support the idea that macrolides have antiviral properties through a mechanism that is yet to be ascertained. We also provide evidence that macrolides can be developed with anti-inflammatory, antibacterial and antiviral activity and show surprising versatility depending on the clinical need.
Date Issued
2016-07-25
Date Acceptance
2016-05-09
Citation
Journal of Antimicrobial Chemotherapy, 2016, 71 (10), pp.2767-2781
URI
http://hdl.handle.net/10044/1/38908
DOI
https://www.dx.doi.org/10.1093/jac/dkw222
ISSN
1460-2091
Publisher
Oxford University Press (OUP)
Start Page
2767
End Page
2781
Journal / Book Title
Journal of Antimicrobial Chemotherapy
Volume
71
Issue
10
Copyright Statement
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
License URL
http://creativecommons.org/licenses/by/4.0/
Sponsor
Medical Research Council (MRC)
Imperial College Healthcare NHS Trust- BRC Funding
GlaxoSmithKline Services Unlimited
Merck Sharp & Dohme Corp
Medical Research Council (MRC)
BBSRC
Identifier
PII: dkw222
Grant Number
G1100238
RDA06
n/a
MK8237-009
MR/L012693/1
BB/1532310/1
Subjects
Microbiology
1115 Pharmacology And Pharmaceutical Sciences
0605 Microbiology
1108 Medical Microbiology
Publication Status
Published
About
Spiral Depositing with Spiral Publishing with Spiral Symplectic
Contact us
Open access team Report an issue
Other Services
Scholarly Communications Library Services
logo

Imperial College London

South Kensington Campus

London SW7 2AZ, UK

tel: +44 (0)20 7589 5111

Accessibility Modern slavery statement Cookie Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback